Bhardwaj, Anshu and Scaria, Vinod and Raghava, Gajendra Pal Singh and Lynn, Andrew Michael and Chandra, Nagasuma and Banerjee, Sulagna and Raghunandanan, Muthukurussi V and Pandey, Vikas and Taneja, Bhupesh and Yadav, Jyoti and Dash, Debasis and Bhattacharya, Jaijit and Misra, Amit and Kumar, Anil and Ramachandran, Srinivasan and Thomas, Zakir and Brahmachari, Samir K (2011) Open source drug discovery- A new paradigm of collaborative research in tuberculosis drug development. In: Tuberculosis, 91 (5, SI). pp. 479-486.
03nov.pdf - Published Version
Restricted to Registered users only
Download (818Kb) | Request a copy
It is being realized that the traditional closed-door and market driven approaches for drug discovery may not be the best suited model for the diseases of the developing world such as tuberculosis and malaria, because most patients suffering from these diseases have poor paying capacity. To ensure that new drugs are created for patients suffering from these diseases, it is necessary to formulate an alternate paradigm of drug discovery process. The current model constrained by limitations for collaboration and for sharing of resources with confidentiality hampers the opportunities for bringing expertise from diverse fields. These limitations hinder the possibilities of lowering the cost of drug discovery. The Open Source Drug Discovery project initiated by Council of Scientific and Industrial Research, India has adopted an open source model to power wide participation across geographical borders. Open Source Drug Discovery emphasizes integrative science through collaboration, open-sharing, taking up multi-faceted approaches and accruing benefits from advances on different fronts of new drug discovery. Because the open source model is based on community participation, it has the potential to self-sustain continuous development by generating a storehouse of alternatives towards continued pursuit for new drug discovery. Since the inventions are community generated, the new chemical entities developed by Open Source Drug Discovery will be taken up for clinical trial in a non-exclusive manner by participation of multiple companies with majority funding from Open Source Drug Discovery. This will ensure availability of drugs through a lower cost community driven drug discovery process for diseases afflicting people with poor paying capacity. Hopefully what LINUX the World Wide Web have done for the information technology, Open Source Drug Discovery will do for drug discovery. (C) 2011 Elsevier Ltd. All rights reserved.
|Item Type:||Journal Article|
|Additional Information:||Copyright of this article belongs to Elsevier Science.|
|Keywords:||Open source;Drug Discovery;Tuberculosis;Malaria;Neglected diseases;Generics|
|Department/Centre:||Division of Information Sciences > BioInformatics Centre|
|Date Deposited:||04 Nov 2011 09:39|
|Last Modified:||15 Jan 2013 06:33|
Actions (login required)